1.Postoperative chemoradiotherapy versus chemotherapy for stageⅡ-Ⅲrectal cancer
Zhennuo MU ; Chao ZHENG ; Huaqing SUN ; Abdukadir ALIYE
Journal of Medical Postgraduates 2015;(1):55-57
Objective Controversy exists over the effects of postoperative chemoradiotherapy or chemotherapy in the treatment of rectal cancer. This study aims to evaluate the clinical effect of chemoradiotherapy or chemotherapy following radical surgery for stage Ⅱ-Ⅲrectal cancer. Methods We retrospectively analyzed the clinical data of 125 cases of stageⅡ-Ⅲrectal cancer receiving chemo-radiotherapy ( n=69) or chemotherapy ( n=56) after radical surgery. The patients in the chemoradiotherapy group were treated by 3-di-mensional conformal or intensity-modulated radiotherapy at a total irradiation dose of 45-50 Gy/25-28 times and concurrently by XE-LOX/FOLFOX chemotherapy for 4-6 cycles. Those in the chemotherapy group underwent XELOX/FOLFOX chemotherapy only, at the same dose and for the same length of time as the former. Results The therapeutic effect on stageⅡ-Ⅲrectal cancer was not correla-ted with the gender, family history, smoking history, drinking history, high-fat intake, sedentariness, obesity or constipation of the pa-tient, nor with the TNM stage, pathological grade or differentiation degree of the disease. The 1-, 2-, and 3-year survival rates were sig-nificantly higher in the chemoradiotherapy group (86. 9%, 76. 8%, and 57. 9%) than in the chemotherapy group (71. 4%, 58. 9%, and 39. 3%) (P<0. 05), while the 1-, 2-, and 3-year recurrence rates were remarkably lower in the former (5. 8%, 11. 6%, and 18. 8%) than in the latter (17. 9%, 26. 8%, and 37. 5%) (P<0. 05). Statistically significant differences were found between the che-moradiotherapy and chemotherapy groups in the incidence of diarrhea (39. 1%vs 14. 3%, P<0. 05), but not in such adverse reactions as bone marrow suppression, nausea, or vomiting (P>0. 05). Conclusion For stageⅡ-Ⅲrectal cancer, postoperative chemoradio-therapy is a safe and effective option , which can evidently reduce local recurrence and improve 3-year survival of the patient.
2.Effects of trichosanthin on apoptosis and cytoskeleton microtubule structure reconfiguration in lung cancer A549 cells
Jing ZHUANG ; Changgang SUN ; Congcong WANG ; Fubin FENG ; Qingliang LV ; Huaqing WANG ; Mianhua WU
Chinese Journal of Clinical Oncology 2014;45(11):693-696
Objective:This study aimed to explore the effects of trichosanthin on the proliferative inhibition and apoptosis induc-tion in human lung carcinoma A549 cells. Methods:A549 cells were treated with various concentrations of TCS. The inhibitory effects in proliferation were detected by the MTT method. The microfilament changes were observed by transmission electron microscopy. Apoptosis rate and cell cycle were determined by flow cytometry. Results:A549 cells treated with TCS presented apoptotic changes and decreased cell activity. When the concentration increased and time was prolonged, the inhibition rate increased correspondingly. Conclusion:Pharmacological doses of TCS inhibited the proliferation and differentiation in lung carcinoma A549 cells and affected the function in A549 cells by changes in the cytoskeleton.
3.Efficacy and safety of aprepitant in prevention of nausea and vomiting induced by chemotherapy in patients with diffuse large B-cell lymphoma
Zhi CHANG ; Teng SONG ; Yarui ZHANG ; Zengmiao SUN ; Yukun QIN ; Huaqing WANG
Journal of Leukemia & Lymphoma 2018;27(1):37-40
Objective To evaluate the efficacy and safety of neurokinin1 (NK1) receptor antagonist aprepitant combined with prednisone and tropisetron in prevention of nausea and vomiting (CINV) induced by R-CHOP or CHOP regimen. Methods A total of 90 patients with diffuse large B-cell lymphoma (DLBCL) who accepted R-CHOP or CHOP regimen in the People''s Hospital of Tianjin from October 2015 to January 2016 were divided into aprepitant group (45 cases) and the control group (45 cases) according to the random number table. In aprepitant group, day 1: aprepitant 125 mg 1 h before chemotherapy, prednison 100 mg, tropisetron 10 mg, and tropisetron 5 mg 2 hours after chemotherapy;day 2-3:aprepitant 80 mg and prednison 100 mg, tropisetron 10 mg; day 4-5: prednison 100 mg. In the control group, day 1: prednison 100 mg 1 h before chemotherapy, tropisetron 10 mg, and tropisetron 5 mg 2 h after chemotherapy; days 2-3: prednison 100 mg, tropisetron 10 mg; day 4-5: prednison 100 mg. Data on nausea, vomiting and remission treatment were collected every day. The complete remission (CR) rates of CINV without vomiting and remission drugs in the whole cycle were recorded. Functional living index-emesis questionnaire (FILE) was used to assess the effect of CINV on the life quality of the patients. Results CR in aprepitant group was higher than that in the control group (77.8 % vs. 55.6 %, χ2= 5.000, P= 0.025). The rate of no vomiting in aprepitant regimen was higher than that in the control regimen (82.2 % vs. 62.2 %, χ2 = 4.486, P= 0.034). The average scores of FILE between the two groups were (113 ±10) and (100 ±11) scores respectively, and there was a significant difference (t=12.437, P<0.001). The related adverse reactions of vomiting-stopping drugs in both groups had no statistical difference. Conclusion The aprepitant combined with tropisetron and prednisone can improve effectively nausea and vomiting induced by R-CHOP or CHOP chemotherapy regimen for DLBCL patients.
4. Epidemiological analysis of viral hepatitis A in China, 2004-2015
Xiaojin SUN ; Fuzhen WANG ; Hui ZHENG ; Ning MIAO ; Qianli YUAN ; Huaqing WANG ; Zundong YIN ; Guomin ZHANG
Chinese Journal of Preventive Medicine 2017;51(12):1091-1096
Objective:
To analyze the epidemiological characteristics of hepatitis A cases in China from 2004 to 2015.
Methods:
Data of hepatitis A were reported through national notifiable disease information reporting system, which covered the 31 provinces (Hong Kong, Macau and Taiwan excluded). The inclusion criteria was: date of illness onset was between January 1st 2004 and December 31st 2015, the status of reported card was confirmed, the case was classified as laboratory confirmed or clinical diagnosed, the disease was Hepatitis A. The information such as sex, date of birth, date of illness onset, place of residence was collected. The data was divided into three phases, 2004-2007, 2008-2011, 2012-2015, which represented the phase before expanded program on immunization (EPI), first 4 years after EPI, second 4 years after EPI.
Results:
From 2004 to 2015, there were totally 574 697 hepatitis A cases in China, the mean annual incidence was 3.62/100 000. The risk ratio of hepatitis A in 2015 was 0.23 when compared with 2004. Sichuan, Xinjiang and Yunnan contributed to 27.27% of the total cases in China. In 2012-2015, the incidence of western (3.46/100 000) region was significantly higher than that in central (1.21/100 000) and eastern (1.08/100 000) regions. From 2004-2015, number of cases in each age group declined greatly, with number of cases declining from 43 711 to 5 938 in the age group of 5-9 years, from 29 722 to 3 438 in 10-14, from 23 212 to 3 646 in 15-19. The number of cases declined from 24 079 to 10 304 in the age group of 0-4 (declined by 57.21%), but in 2012-2015, the incidence of 0-4 age group was still the highest, with 77.72% cases in Xinjiang and Sichuan. Famers, students and scattered children accounted for 69.95% of total cases, with student cases declined from 24.08% (2004-2007) to 8.67% (2012-2015).
Conclusion
The incidence of hepatitis A in China is decreasing year by year, the risk has been decreasing to a relatively low level. However, in western regions and children under age five, the risk is still high. Precision intervention is needed for further prevention and control of hepatitis A.
5. Epidemiological analysis of viral hepatitis E in China, 2004-2017
Xiaojin SUN ; Guomin ZHANG ; Hui ZHENG ; Ning MIAO ; Huaqing WANG ; Zundong YIN ; Fuzhen WANG
Chinese Journal of Preventive Medicine 2019;53(4):382-387
Objective:
To analyze the changing epidemiological characteristics of hepatitis E cases in China, in order to promote in preventing and controlling hepatitis E.
Methods:
Data of hepatitis E and outbreaks reported through national notifiable diseases reporting system were analyzed from 2004 to 2017, but data of Hongkong, Macau and Taiwan were not included. Data of hepatitis E were divided into three phases as 2004-2007, 2008-2011 and 2012-2017, representing eight years before, four years before and years after the postmarketing of hepatitis E vaccine. Linear regression was used for analyzing the trend of hepatitis E, improved muster method was used for analyzing the seasonal intensity.
Results:
From 2004 to 2017, 329 519 hepatitis E cases were reported and the annual incidence were increasing from 1.27/100 000 to 2.10/100 000 (
6. Comparative analyze on hepatitis B seroepidemiological surveys among population aged 1-29 years in different epidemic regions of China in 1992 and 2014
Fuzhen WANG ; Guomin ZHANG ; Liping SHEN ; Hui ZHENG ; Feng WANG ; Ning MIAO ; Qianli YUAN ; Xiaojin SUN ; Shengli BI ; Xiaofeng LIANG ; Huaqing WANG
Chinese Journal of Preventive Medicine 2017;51(6):462-468
Objective:
To evaluate the effect of hepatitis B prevention and control by comparative analysis on the results of HBsAg, anti-HBs and anti-HBc prevalence from national hepatitis B seroepidemiological surveys in 1992 and 2014 in different epidemic regions of China.
Methods:
Data was from the national seroepidemiological surveys of hepatitis B conducted in 1992 and 2014. The survey in 1992 was conducted in 145 disease surveillance points of 30 provinces (excluding Hong Kong, Macao Special Administrative Region and Taiwan province) in China. The survey in 2016 was conducted in 160 disease surveillance points of 31 provinces (excluding Hong Kong, Macao Special Administrative Region and Taiwan province) in China. In the two surveys, face-to-face interviews with the subject by door to door or on the investigation site were conducted by trained staff using standard questionnaires to obtain basic information including birth date, gender, ethnicity, resident place and so on. And then 5 ml venous blood was collected to test the sero-markers of HBsAg, anti-HBs and anti-HBc. We analyzed unweighted point prevalence and 95
7.Factors affecting the elevation of inter-arm systolic blood pressure difference in a physical examination population
Xiaoyu ZHANG ; Haoxiang SUN ; Huaqing HU ; Yue ZHANG ; Yuting LEI ; Yuling ZHANG ; Shuang ZHAO
Chinese Journal of Health Management 2022;16(5):298-302
Objective:To analyze the related factors affecting the inter-arm systolic blood pressure difference (IASBPD) in a physical examination population.Methods:A total of 3 600 adults who underwent physical examination and completed the arteriosclerosis test in the first affiliated hospital of Anhui medical university from January 2019 to June 2021 were selected as the participants by systematic sampling method. Data on age, sex, and history of smoking, heavy drinking, hypertension, type 2 diabetes, and coronary heart disease were recorded. The height, weight, waist circumference, hip circumference, total muscle, total fat and body fat ratio were measured, and body mass index was calculated. The blood pressure of the limbs, ankle brachial index (ABI) were measured synchronously with the arteriosclerosis tester of the Chinese Academy of Sciences, and the IASBPD were calculated. According to the IASBPD value, the participants were divided into two groups: IASBPD<10 mmHg (1 mmHg=0.133 kPa) group and IASBPD≥10 mmHg group, The differences between the two groups were compared, and the related influencing factors of IASBPD were analyzed by multivariate logistic regression.Results:Weight, body mass index, waist circumference, hip circumference, systolic blood pressure, diastolic blood pressure, total muscle, total fat, body fat rate, history of hypertension, proportion of type 2 diabetes mellitus, and proportion of history of coronary heart disease in the IASBPD≥10 mmHg group was higher than that of IASBPD<10 mmHg group [(69.1±11.2) vs (65.3±10.8) kg, (25.6±3.4) vs (24.4±3.3) kg/m 2, (91.3±11.3) vs (87.8±10.6) cm, (98.5±10.4) vs (96.5±9.8) cm, (139.7±20.0) vs (129.7±17.6) mmHg, (80.3±11.6) vs (76.7±10.1) mmHg, (47.5±9.1) vs (45.3±8.8) kg, (19.4±7.0) vs (17.6±6.4) kg, (27.9%±8.5%) vs (26.8%±8.1%), 41.1% vs 29.3%, 16.6% vs 11.7%, 13.1% vs 7.3%] (all P<0.05); ABI was lower than that in IASBPD<10 mmHg group [(1.15±0.11) vs (1.20±0.09)] ( P<0.001). There were no significant differences in height, smoking history and heavy drinking history between the two groups (all P>0.05). Multivariate logistic regression analysis showed that age, systolic blood pressure, body weight and ABI were independent influencing factors of IASBPD≥10 mmHg. Age, systolic blood pressure and body weight were positively correlated with IASBPD≥10 mmHg, while ABI was negatively correlated with IASBPD≥10 mmHg. Conclusion:Increases in age, systolic blood pressure, and body weight and a decrease in ABI are important influencing factors leading to the elevation of IASBPD.
8.Summary of the best evidence for the energy and protein intake targets and calculation in critically ill patients
Yingying DENG ; Ying REN ; Weijie WANG ; Rui SUN ; Huaqing PEI ; Huijuan SONG
Chinese Critical Care Medicine 2023;35(8):849-855
Objective:To evaluate and summarize the best evidence of energy and protein intake targets and calculation in adult critically ill patients, and to provide evidence-based basis for critical nutrition management.Methods:Evidence related to energy and protein intake targets and calculation of adult critically ill patients, including guideline, expert consensus, systematic review and evidence summary, were systematically searched in PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, Cochrane Library, UpToDate, BMJ Best Practice, Joanna Briggs Institute (JBI), Web of Science, SinoMed, Medive, China National Knowledge Infrastructure, Wanfang database, VIP database, Guidelines International Network (GIN), National Institute for Health and Care Excellence (NICE), National Guideline Clearinghouse (NGC), Registered Nurses Association of Ontario (RNAO), and Society of Critical Care Medicine (SCCM) from January 2012 to June 2022. Two researchers independently evaluated the quality of the included literatures using the JBI Evidence-based Health Care Center evaluation tool and the Appraisal of Clinical Practice Guidelines for Research and Evaluation Ⅱ (AGREE Ⅱ), extracted and summarized the best evidence for the nutritional intake goal and calculation of adult critically ill patients, and described the evidence.Results:A total of 18 literatures were included, including 5 clinical guidelines, 8 expert consensus, 3 systematic reviews and 2 evidence summaries. After literature quality evaluation, 18 articles were all enrolled. The evidence was summarized from the four aspects, including energy target calculation method, dose body weight, energy and protein intake target, and calculation method, 24 pieces of the best evidence were finally formed.Conclusions:The best evidence of energy and protein intake targets and calculation for critically ill patients was summarized based on evidence-based. Clinical medical staff can choose indirect calorimetry to calculate energy goals when equipment is available. Patient's height, body weight should be recorded accurately, dose body weight can be determined by body mass index (BMI). Meanwhile, blood urea nitrogen (BUN) loss, fat-free body weight, simple formulas and other methods should be used to continuously evaluate and adjust protein intake targets, to achieve the purpose of optimizing intensive nutrition support.
9.Progress in Development of Dose Verification System Software KylinRay-Dose4D.
Huaqing ZHENG ; Guangyao SUN ; Yun ZHAO ; Bo XIAO ; Jing JIA ; Tao HE ; Pengcheng LONG ; Liqin HU
Chinese Journal of Medical Instrumentation 2023;47(4):360-364
Advanced radiotherapy technology enables the dose to more accurately conform to the tumor target area of the patient, providing accurate treatment for the patient, but the gradient of the patient's radiation dose at the tumor edge is getting larger, which putting forward higher requirements for radiotherapy dose verification. The dose verification system software KylinRay-Dose4D can verify the patient's pre-treatment plan and the in vivo/on-line dose during the patient's treatment, providing important reference for the physicist to modify the radiotherapy plan and ensuring that the patient receives accurate treatment. This study introduces the overall design and key technologies of KylinRay-Dose4D, and tests the pre-treatment plan dose checking calculation and 2D/3D dose verification through clinical cases. The test results showed that the 2D/3D gamma pass rate (3 mm/3%) of KylinRay-Dose4D reconstructed dose compared with TPS plan dose and measured dose is larger than 95%, which indicating that the reconstructed dose of KylinRay-Dose4D meets the requirement of clinical application.
Humans
;
Radiotherapy Dosage
;
Radiotherapy Planning, Computer-Assisted/methods*
;
Radiotherapy, Intensity-Modulated/methods*
;
Software
;
Neoplasms
;
Phantoms, Imaging
;
Radiometry/methods*
10.TMEM16A inhibits angiotensin II-induced basilar artery smooth muscle cell migration in a WNK1-dependent manner.
Huaqing ZHENG ; Xiaolong LI ; Xin ZENG ; Chengcui HUANG ; Mingming MA ; Xiaofei LV ; Yajuan ZHANG ; Lu SUN ; Guanlei WANG ; Yanhua DU ; Yongyuan GUAN
Acta Pharmaceutica Sinica B 2021;11(12):3994-4007
Vascular smooth muscle cell (VSMC) migration plays a critical role in the pathogenesis of many cardiovascular diseases. We recently showed that TMEM16A is involved in hypertension-induced cerebrovascular remodeling. However, it is unclear whether this effect is related to the regulation of VSMC migration. Here, we investigated whether and how TMEM16A contributes to migration in basilar artery smooth muscle cells (BASMCs). We observed that AngII increased the migration of cultured BASMCs, which was markedly inhibited by overexpression of TMEM16A. TMEM16A overexpression inhibited AngII-induced RhoA/ROCK2 activation, and myosin light chain phosphatase (MLCP) and myosin light chain (MLC20) phosphorylation. But AngII-induced myosin light chain kinase (MLCK) activation was not affected by TMEM16A. Furthermore, a suppressed activation of integrin